Radiopharm Theranostics Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Key Metrics
PE ratio
-
PB ratio
1.16
Dividend yield
-
Beta
0.86
Market cap
$52.03M
Enterprise value
$23.36M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 14 |
| Website | https://www.radiopharmtheranostics.com |
| Mailing address | 62 Lygon Street Level 3 Carlton VIC 3053 Australia |
| Phone / Fax | 61 3 9824 5254 / 61 3 9822 7735 |
Dividends
More: Radiopharm Theranostics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Radiopharm Theranostics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.RAD dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Radiopharm Theranostics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder & Executive Chairman | 69 | |
| Mr. Riccardo Canevari | MD, CEO & Director | ||
| Mr. Phillip Hains | CFO & Joint Company Secretary | ||
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer | 62 | |
| Mr. Hitesh Goel | Head of Project Management | ||
| Mr. Nathan Jong C.A. | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-152.11%
Return on assets
-27.70%
Return on equity
-109.20%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Radiopharm Theranostics is 52.03M and its enterprise value is 23.36M. The enterprise value to revenue ratio of RAD is 1.87. The enterprise value to EBITDA ratio of RAD is -0.72.
The RAD's stocks Beta value is 0.86 making it 14% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Radiopharm Theranostics (RAD)
Radiopharm Theranostics (ASX:RAD) Frequently Asked Questions
1. What is Radiopharm Theranostics's Stock Symbol?
Radiopharm Theranostics trades on ASX under the ticker symbol "RAD".
2. What is Radiopharm Theranostics's stock price today?
One share of RAD stock can currently be purchased for approximately $0.022.
3. How can I contact Radiopharm Theranostics?
Radiopharm Theranostics's mailing address is 62 Lygon Street Level 3 Carlton VIC 3053 Australia. The company can be reached via phone at 61 3 9824 5254.
4. What is Radiopharm Theranostics's official website?
The official website of Radiopharm Theranostics is https://www.radiopharmtheranostics.com.